Tetraphase receives BARDA contract to develop new antibiotic
Tetraphase Pharmaceuticals has received $67m contract from Biomedical Advanced Research and Development Authority (BARDA) for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens.
The BARDA contract includes pre-clinical efficacy and toxicology studies; clinical studies; manufacturing activities; and associated regulatory activities of TP-434.
The contract includes a 12-month base period with committed funding of $11.5m and subsequent option periods that, if completed, would bring the total value of the award to approximately $67m.
Tetraphase will work on this contract with CUBRC, the company said.
TP-434 as a potential empiric countermeasure for the treatment of inhalational disease caused by Bacillus anthracis, Francisella tularensis and Yersinia pestis.
Tetraphase president and CEO Guy Macdonald said BARDA's award covering the development of TP-434 brings the total federal funding in support of the development of Tetraphase's antibiotics to more than $100m.
Latest News
Related News
Contract Research & Services> Contract Research
Related Dates
2012> February
Related Industries
Pharmaceuticals and Healthcare> Services> Outsourced Services> Contract Research Organization> Contract research
Related Insight
Suppliers Directory
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Contract Research Intelligence
API research into pharmaceutical companies and corporations Buy online from $200

Comments may be moderated for spam, obscenities or defamation.